PolyNovo

Historical price data

PolyNovo is a commercial-stage medical device company with a mission to improve patient outcomes in complex wound management through its innovative NovoSorb® biodegradable polymer platform. Its key achievement is the successful global commercialization of NovoSorb BTM, a synthetic dermal substitute that addresses significant limitations of autografts and biological materials. The company's strategy focuses on expanding geographic reach, driving deeper market penetration in surgical wound care, and leveraging its polymer platform for new product development. PolyNovo is publicly traded on the ASX and has established a direct commercial presence in key markets including the US, Australia, and Europe.

NovoSorb® is a proprietary family of synthetic, biodegradable polyurethane polymers engineered to act as a temporary scaffold for tissue regeneration, which safely hydrolyzes and is absorbed by the body over time.

PolyNovo competes in the advanced wound care market against giants like Integra LifeSciences, Smith & Nephew, and 3M. Its primary competitive advantages are its purely synthetic, consistent NovoSorb BTM product, a focused direct sales model providing deep clinical support, and a versatile polymer platform enabling internal pipeline development.